Hairgain 5%

/ Perrigo

Solution: Apply 1 ml twice a day to the scalp.
Foam: Apply 1 gr twice a day to the scalp.
See package insert (OTC).

Hair regrowth treatment for men.

Women, hypersensitivity to any of the ingredients.

* Before using minoxidil, the user should determine that the scalp is normal and healthy. Topical minoxidil should not be applied to inflamed, infected, irritated or painful scalp skin.
* Topical minoxidil is not indicated when there is no family history of hair loss, hair loss is sudden and/or patchy, hair loss is due to childbirth, or the reason for hair loss is unknown.
* Discontinue this medical product and evaluate the patient if hypotension is detected, or if the patient develops chest pain, tachycardia, syncope or dizziness, sudden unexplained weight gain, peripheral oedema, persistent erythema or scalp irritation, or any other unexpected new symptoms.
* Some patients have experienced changes in hair colour and/or texture with this product use.
* This medical product is for external use only. Do not apply to areas of the body other than the scalp.
* Some consumers reported increased hair shedding upon initiation of therapy with. This is most likely due to minoxidil’s action of shifting hairs from the resting telogen phase to the growing anagen phase (old hairs fall out as new hairs grow in their place). This temporary increase in hair shedding generally occurs two to six weeks after beginning treatment and subsides within a couple of weeks.
* Accidental ingestion may cause serious cardiac adverse events. Therefore, this product has to be kept out of the reach of children.
* This medical product contains ethanol (alcohol), which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin and mucous membranes) the area should be bathed with large amounts of cool tap water.
* This medical product also contains butylated hydroxytoluene, which may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes or mucous membranes, and cetyl and stearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis).
* Hypertrichosis in children following inadvertent topical exposure to minoxidil: Cases of hypertrichosis have been reported in infants following skin contact with minoxidil application sites of patients (caregivers) using topical minoxidil. Hypertrichosis was reversible, within months, when infants were no longer exposed to minoxidil. Contact between children and minoxidil application sites should therefore be avoided.
See prescribing information for full details.

Common: Hypersensitivity reactions (including: face oedema, generalised erythema, pruritus generalised, swelling face, and throat tightness), Chest pain, Hypertrichosis (unwanted non-scalp hair including facial hair growth in women), Pruritus (including rash pruritic generalised and eye pruritus), Rash (including pustular, papular, generalised, vestibular and macular rash), Dermatitis (including contact, allergic, atopic and seborrhoeic dermatitis), Oedema peripheral, Weight increased.
Very common: Headache
See prescribing information for full details.

This product should not be used concomitantly with other medications applied topically on the scalp. Topical drugs, such as corticosteroids, tretinoin, dithranol or petrolatum, which alter the stratum corneum barrier, could result in increased absorption of minoxidil if applied concurrently. Although it has not been demonstrated clinically, there exists the theoretical possibility of absorbed minoxidil potentiating orthostatic hypotension caused by peripheral vasodilators. Guanethidine has been reported to interact with oral formulations of minoxidil resulting in rapid and pronounced lowering of blood pressure. There is a theoretical possibility that topical minoxidil may also interact with guanethidine.

This product should not be used during pregnancy or lactation.
See prescribing information for full details